Search results
Added:
11 months ago
Source:
Radcliffe Cardiology
A new nationwide cohort study from France suggests that a simple risk stratification tool based on administrative data could help tailor cardiologist follow-up for patients with heart failure (HF), potentially improving survival and optimising resource use. The study found that 40% of patients with HF do not have an annual cardiology consultation, regardless of their disease severity.¹The French…
View more
Added:
11 months ago
Source:
Radcliffe Cardiology
The global economic burden of heart failure (HF) reached an estimated $284.17 billion in 2021, highlighting a substantial and growing financial strain on healthcare systems and societies worldwide. A new systematic review reveals that indirect costs, such as productivity loss, now account for over half of this total, signalling a significant shift in the economic impact of the condition…
View more
Added:
1 year ago
Source:
Radcliffe CKM
A recent study published in Circulation: Heart Failure1 has found that multimorbidity, the presence of two or more chronic health conditions, substantially increases the risk of mortality in patients with heart failure who have mildly reduced (HFmrEF) or preserved ejection fraction (HFpEF).The study analyzed data from two major heart failure trials: TOPCAT-Americas (Treatment of Preserved Cardiac…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
Frailty is a common and significant factor associated with adverse outcomes in patients with heart failure, but the prognostic utility of simple assessment tools in contemporary practice remains an area of investigation. A new study using data from a large Japanese registry has found that the Clinical Frailty Scale (CFS) effectively captures both physical and cognitive decline and is an…
View more
PANDA II: In-hospital Influenza Vaccination Reduces Mortality and Readmission in Acute Heart Failure
Added:
10 months ago
Source:
Radcliffe Cardiology
News
Added:
2 months ago
Source:
Heart Failure Academy
The European Commission has approved the non-steroidal mineralocorticoid receptor antagonist (nsMRA) finerenone (Kerendia) for the treatment of adults with symptomatic chronic heart failure (HF) and a left ventricular ejection fraction (LVEF) of ≥40%.¹ The approval is based on positive results from the Phase III Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients…
View more
Added:
6 months ago
Source:
Radcliffe Cardiology
An exploratory analysis of the VICTOR trial suggests that in compensated patients with heart failure and reduced ejection fraction (HFrEF), vericiguat may reduce the overall burden of worsening heart failure (HF) when outpatient events are included alongside hospitalisations.¹Vericiguat is an oral soluble guanylate cyclase stimulator that enhances the cyclic guanosine monophosphate pathway,…
View more
Added:
4 months ago
Source:
Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes…
View more
Added:
5 months ago
Source:
Radcliffe Cardiology
A new study has revealed significant delays in the diagnosis of transthyretin amyloid cardiomyopathy (ATTR-CM) following an initial diagnosis of heart failure (HF), with the median time to diagnosis exceeding one year.¹ Timely identification of ATTR-CM is critical to reduce morbidity and mortality, as effective treatments are available.²MethodologyThis retrospective cohort study analysed data…
View more
Added:
3 months ago
Source:
Arrhythmia and Electrophysiology Review
For patients with heart failure (HF) and left bundle-branch block (LBBB), left bundle-branch pacing (LBBP) has been proposed as an alternative to the standard biventricular pacing (BiVP).¹ A new randomised trial, HeartSync-LBBP, has found that LBBP leads to superior long-term clinical outcomes compared with BiVP in this patient population.²MethodologyThe HeartSync-LBBP trial was a multicentre,…
View more